about
Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis.First-line therapies in inflammatory bowel disease.Therapy of steroid-resistant inflammatory bowel disease.Treatment of fibrostenotic and fistulizing Crohn's disease.Eosinophils in the gastrointestinal tract: friends or foes?Activity assessment of eosinophilic esophagitis.How to measure disease activity in eosinophilic esophagitis.High altitude journeys and flights are associated with an increased risk of flares in inflammatory bowel disease patients.Escalating incidence of eosinophilic esophagitis in Canton of Vaud, Switzerland, 1993-2013: a population-based study.Long-Term Treatment of Eosinophilic Esophagitis With Swallowed Topical Corticosteroids: Development and Evaluation of a Therapeutic Concept.Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study.Eosinophilic Esophagitis: Impact of Latest Insights Into Pathophysiology on Therapeutic Strategies.Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment.Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up.Prevalence and risk factors for venous thromboembolic complications in the Swiss Inflammatory Bowel Disease Cohort.The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma.Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients.Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort.How do gastroenterologists assess overall activity of eosinophilic esophagitis in adult patients?Eosinophilic oesophagitis: relationship of quality of life with clinical, endoscopic and histological activity.Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease.Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes.Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort.Swallowed topical corticosteroids reduce the risk for long-lasting bolus impactions in eosinophilic esophagitis.Symptoms Have Modest Accuracy in Detecting Endoscopic and Histologic Remission in Adults With Eosinophilic Esophagitis.Eosinophilic Esophagitis: Relationship of Subepithelial Eosinophilic Inflammation With Epithelial Histology, Endoscopy, Blood Eosinophils, and Symptoms.Pharmacologic Treatment of Eosinophilic Esophagitis: An Update.Latest Insights on the Relationship Between Symptoms and Biologic Findings in Adults with Eosinophilic Esophagitis.Comparison of different biopsy forceps models for tissue sampling in eosinophilic esophagitis.A new eosinophilic esophagitis (EoE)-like disease without tissue eosinophilia found in EoE families.Patient-Reported Outcomes in Eosinophilic Esophagitis and Achalasia.A shift from oral to intravenous iron supplementation therapy is observed over time in a large swiss cohort of patients with inflammatory bowel disease.Eosinophile Oesophagitis.Delay in Diagnosis of Eosinophilic Esophagitis Increases Risk for Stricture Formation in a Time-Dependent MannerA cysteine-free firefly luciferase retains luminescence activityDendritic cells derived from murine colonic mucosa have unique functional and phenotypic characteristicsColorectal polypectomy during insertion and withdrawal or only during withdrawal? A randomized controlled trialEosinophilic oesophagitis and proton pump inhibitor-responsive oesophageal eosinophilia have similar clinical, endoscopic and histological findingsFrequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort
P50
Q33456102-479A63D3-F090-4B48-8BBA-8D6AEE01F7DBQ35586286-B0241173-C7AA-4159-9832-7518A85ACC8AQ38050878-8932CF37-C6C9-49A2-89ED-4EDD3D65006DQ38050879-B62F33F5-2ACE-4975-B8D0-08D0FCED6BF7Q38050883-7CF285A8-B99D-4503-A333-E3D0B102BC2FQ38053440-86DBFE08-D879-419B-BCD9-2BFB489623C7Q38194016-E81BC7FF-7C24-4267-9348-29558F2AB79DQ38557900-69272F83-1EA8-43C6-ABBE-9BDC42830EEAQ38565092-2E4FA450-25ED-42EF-9071-178A3646C43BQ38573151-1CE9B2E1-F386-44CD-B858-8CE030266422Q38673788-FD1A555E-B150-4CA8-A219-3F7DA87095FBQ38814948-0F174544-B755-4A52-81B5-B907D591A8F7Q38849709-BC9BA4A4-1931-4EAC-B799-42111FD6ADE0Q39227829-23AB0B96-E580-4C3B-97BC-AF18BB1ABBC3Q39396350-07B2AB6E-4A7D-435A-8B84-2915B8CC16F7Q39745686-A7459F2F-6415-4F56-BC27-1AA64CC94B86Q40378381-03EC850D-AB6A-4FE2-85A4-401AD6658C2FQ40764556-354B7B7F-B069-4065-B5A0-24643C426BBFQ40893795-3089C96F-BB98-4583-AA60-FFF2FA7CE9D8Q41319565-BF503096-F781-4F5C-A476-67F54F1E8909Q41484757-FF321D6D-3775-4E39-9867-FE64BF946D58Q41485105-FFA9138F-FCAC-4A45-B40B-4B6BEF2CDCD0Q43996419-6E1E2EF4-26DD-4480-89B2-8378218199ABQ45151393-DF300EAA-1724-4E87-A1B6-17DFA5A2B5DEQ46031657-A28C2A3B-587C-4031-BC59-E11F73607A34Q46789131-D66CABE3-3C87-4230-8A63-77381C916558Q47559116-6EAFFFC4-7C5F-4CF4-B618-79B0E2FFB782Q47617305-29B042D2-D3B0-4BA6-BAC4-6624AA5B647AQ47617317-0C0E211D-76D4-42A7-8A08-F257A158E183Q50124855-AB3AA42F-D7E2-4061-90C5-B3212B42FC1AQ50225864-B26C1D15-736E-4E1F-B887-D996315195E0Q50236635-73C908F8-9355-4F91-8DB8-5C1659A7F7F9Q51271971-B12BBF44-F0E2-4500-BB9C-3740F5074FA4Q51760219-4C1C5113-B269-4223-8509-527E2B87FB68Q61959718-EBAB689C-BE5D-47AC-AEDC-08BD54C111FDQ73330085-D3C121C6-E2CB-477E-AFE7-F67DAC5FD4AAQ80427998-2EDC22B8-88EE-4FC4-BA01-CDC1222992D0Q84890568-A7B848D4-DF02-40CD-AE14-138CC9C06D33Q87160809-D7045E93-0853-459A-8D5A-E430DBFB37D4Q87652070-1D8A8E06-43DF-4930-BEB5-FF9EDBC833E0
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ekaterina Safroneeva
@ast
Ekaterina Safroneeva
@en
Ekaterina Safroneeva
@es
Ekaterina Safroneeva
@nl
type
label
Ekaterina Safroneeva
@ast
Ekaterina Safroneeva
@en
Ekaterina Safroneeva
@es
Ekaterina Safroneeva
@nl
prefLabel
Ekaterina Safroneeva
@ast
Ekaterina Safroneeva
@en
Ekaterina Safroneeva
@es
Ekaterina Safroneeva
@nl
P106
P31
P496
0000-0002-1505-7750